[go: up one dir, main page]

RU2018102365A3 - - Google Patents

Download PDF

Info

Publication number
RU2018102365A3
RU2018102365A3 RU2018102365A RU2018102365A RU2018102365A3 RU 2018102365 A3 RU2018102365 A3 RU 2018102365A3 RU 2018102365 A RU2018102365 A RU 2018102365A RU 2018102365 A RU2018102365 A RU 2018102365A RU 2018102365 A3 RU2018102365 A3 RU 2018102365A3
Authority
RU
Russia
Application number
RU2018102365A
Other versions
RU2018102365A (ru
RU2734418C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018102365A publication Critical patent/RU2018102365A/ru
Publication of RU2018102365A3 publication Critical patent/RU2018102365A3/ru
Application granted granted Critical
Publication of RU2734418C2 publication Critical patent/RU2734418C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018102365A 2015-06-23 2016-06-22 Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их RU2734418C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1555752 2015-06-23
FR1555752A FR3037957B1 (fr) 2015-06-23 2015-06-23 Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/EP2016/064433 WO2016207225A1 (en) 2015-06-23 2016-06-22 New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them

Publications (3)

Publication Number Publication Date
RU2018102365A RU2018102365A (ru) 2019-07-23
RU2018102365A3 true RU2018102365A3 (ru) 2019-09-23
RU2734418C2 RU2734418C2 (ru) 2020-10-16

Family

ID=54608634

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018102365A RU2734418C2 (ru) 2015-06-23 2016-06-22 Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их

Country Status (43)

Country Link
US (2) US10227358B2 (ru)
EP (1) EP3313851B1 (ru)
JP (1) JP6741697B2 (ru)
KR (1) KR102718253B1 (ru)
CN (1) CN107709333B (ru)
AR (1) AR105103A1 (ru)
AU (1) AU2016282836B2 (ru)
BR (1) BR112017027414B1 (ru)
CA (1) CA2990088C (ru)
CL (1) CL2017003258A1 (ru)
CO (1) CO2017012786A2 (ru)
CR (1) CR20170564A (ru)
CU (1) CU20170160A7 (ru)
CY (1) CY1122542T1 (ru)
DK (1) DK3313851T3 (ru)
EA (1) EA033266B1 (ru)
EC (1) ECSP17081744A (ru)
ES (1) ES2759480T3 (ru)
FR (1) FR3037957B1 (ru)
GE (2) GEAP201914678A (ru)
HK (1) HK1249506A1 (ru)
HR (1) HRP20200107T1 (ru)
HU (1) HUE047889T2 (ru)
IL (1) IL256270A (ru)
JO (1) JO3675B1 (ru)
MA (1) MA42239B1 (ru)
MD (1) MD3313851T2 (ru)
MX (1) MX372716B (ru)
MY (1) MY190561A (ru)
PE (1) PE20180742A1 (ru)
PH (1) PH12017502246A1 (ru)
PL (1) PL3313851T3 (ru)
PT (1) PT3313851T (ru)
RS (1) RS59904B1 (ru)
RU (1) RU2734418C2 (ru)
SI (1) SI3313851T1 (ru)
SV (1) SV2017005587A (ru)
TN (1) TN2017000511A1 (ru)
TW (1) TWI604844B (ru)
UA (1) UA122228C2 (ru)
UY (1) UY36736A (ru)
WO (1) WO2016207225A1 (ru)
ZA (1) ZA201708460B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UY37342A (es) 2016-07-22 2018-01-31 Servier Lab Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
WO2018126898A1 (zh) * 2017-01-05 2018-07-12 河南美泰宝生物制药有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
ES2975274T3 (es) * 2017-01-06 2024-07-04 Servier Lab Combinación de un inhibidor de MCL-1 y un compuesto de taxano, sus usos y composiciones farmacéuticas
BR112019026959A2 (pt) 2017-06-22 2020-07-07 Les Laboratoires Servier combinação de um inibidor de mcl-1 e um tratamento com padrão de atendimento para cânceres hematológicos, seus usos e composições farmacêuticas
CN112533598A (zh) * 2017-08-15 2021-03-19 艾伯维公司 大环mcl-1抑制剂和使用方法
CA3073112A1 (en) 2017-08-15 2019-02-21 Abbvie Inc. Macrocyclic mcl-1 inhibitors and methods of use
CN111372936B (zh) * 2017-11-23 2022-12-02 北京赛林泰医药技术有限公司 Mcl-1选择性抑制剂及其制备和用途
CN108424417B (zh) * 2017-12-21 2019-09-20 河南真实生物科技有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
CN110964034B (zh) * 2018-09-29 2022-04-12 江苏恒瑞医药股份有限公司 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用
CN111187277B (zh) * 2018-11-14 2022-04-12 江苏恒瑞医药股份有限公司 噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
TWI849001B (zh) 2018-11-14 2024-07-21 法商施維雅藥廠 Mcl-1抑制劑及米哚妥林(midostaurin)之組合,其用途及醫藥組合物
RS65047B1 (sr) * 2018-12-06 2024-02-29 Servier Lab Novi kristalni oblici tienopirimidina kao inhibitori mcl-1
AU2020279979A1 (en) 2019-05-20 2021-11-25 Les Laboratoires Servier Mcl-1 inhibitor antibody-drug conjugates and methods of use
AR119156A1 (es) 2019-06-17 2021-11-24 Servier Lab Combinación de un inhibidor de mcl-1 y un tratamiento estándar de atención médica para cáncer de mama, usos y composiciones farmacéuticas de la misma
CN114746428B (zh) * 2019-10-03 2025-05-16 加利福尼亚技术学院 Mcl1抑制剂及其应用
CN117136076A (zh) 2020-11-24 2023-11-28 诺华股份有限公司 Mcl-1抑制剂抗体药物缀合物和使用方法
WO2022216946A1 (en) * 2021-04-07 2022-10-13 California Institute Of Technology Mcl1 inhibitors and uses thereof
TWI861509B (zh) 2021-06-11 2024-11-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合
JP2024520801A (ja) 2021-06-11 2024-05-24 ギリアード サイエンシーズ, インコーポレイテッド Mcl-1阻害剤と抗がん剤との組み合わせ
CN113651663B (zh) * 2021-08-20 2024-03-29 浙大宁波理工学院 一种氘代芳香羰基类化合物的制备方法
US20240401146A1 (en) 2021-10-06 2024-12-05 Institut National de la Santé et de la Recherche Médicale Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
IL317101A (en) 2022-05-20 2025-01-01 Novartis Ag Antibody-drug conjugates of anticancer compounds and methods of using them
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
WO2025126157A1 (en) 2023-12-15 2025-06-19 Advesya Anti-il-1rap binding domains and antibody-drug conjugates thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
ES2559779T3 (es) * 2003-08-29 2016-02-15 Vernalis (R&D) Limited Compuestos de pirimidotiofeno
CN102161663B (zh) * 2008-03-05 2014-03-19 梅特希尔基因公司 蛋白酪氨酸激酶活性的抑制剂
CN102464667B (zh) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
TWI604844B (zh) 2017-11-11
CR20170564A (es) 2018-02-20
CY1122542T1 (el) 2021-01-27
PL3313851T3 (pl) 2020-05-18
BR112017027414B1 (pt) 2023-12-19
TN2017000511A1 (en) 2019-04-12
HK1249506A1 (zh) 2018-11-02
PE20180742A1 (es) 2018-04-27
SV2017005587A (es) 2018-04-11
US20190161496A1 (en) 2019-05-30
CN107709333A (zh) 2018-02-16
US10711010B2 (en) 2020-07-14
MY190561A (en) 2022-04-27
JO3675B1 (ar) 2020-08-27
JP2018522855A (ja) 2018-08-16
GEAP201914678A (en) 2019-11-11
RU2018102365A (ru) 2019-07-23
ZA201708460B (en) 2021-06-30
US20180170947A1 (en) 2018-06-21
HRP20200107T1 (hr) 2020-04-03
EA033266B1 (ru) 2019-09-30
RU2734418C2 (ru) 2020-10-16
HUE047889T2 (hu) 2020-05-28
GEP20207074B (en) 2020-03-10
AR105103A1 (es) 2017-09-06
US10227358B2 (en) 2019-03-12
KR102718253B1 (ko) 2024-10-16
UA122228C2 (uk) 2020-10-12
HK1254657A1 (en) 2019-07-26
FR3037957A1 (ru) 2016-12-30
RS59904B1 (sr) 2020-03-31
CL2017003258A1 (es) 2018-06-01
UY36736A (es) 2016-12-30
CA2990088A1 (en) 2016-12-29
AU2016282836A1 (en) 2018-01-18
FR3037957B1 (fr) 2019-01-25
CA2990088C (en) 2021-04-13
CU20170160A7 (es) 2018-05-08
PH12017502246B1 (en) 2018-05-28
BR112017027414A2 (pt) 2018-08-28
EA201890125A1 (ru) 2018-06-29
EP3313851A1 (en) 2018-05-02
MD3313851T2 (ro) 2020-02-29
IL256270A (en) 2018-02-28
AU2016282836B2 (en) 2020-07-09
EP3313851B1 (en) 2019-11-06
PH12017502246A1 (en) 2018-05-28
DK3313851T3 (da) 2020-01-27
PT3313851T (pt) 2020-01-06
WO2016207225A1 (en) 2016-12-29
MX372716B (es) 2020-05-28
KR20180019223A (ko) 2018-02-23
NZ738455A (en) 2024-03-22
ECSP17081744A (es) 2018-02-28
MA42239B1 (fr) 2020-02-28
ES2759480T3 (es) 2020-05-11
MX2017016997A (es) 2018-09-07
SI3313851T1 (sl) 2020-03-31
CN107709333B (zh) 2021-01-01
CO2017012786A2 (es) 2018-04-10
TW201709911A (zh) 2017-03-16
JP6741697B2 (ja) 2020-08-19

Similar Documents

Publication Publication Date Title
RU2018102365A3 (ru)
AU2022228198B1 (ru)
BE2015C047I2 (ru)
BE2015C044I2 (ru)
BR0002435B1 (ru)
CN303069369S (ru)
BR0008604B1 (ru)
BR0008158B1 (ru)
BR0008132B1 (ru)
BR0007834B1 (ru)
BR0007747B1 (ru)
BR0007688B1 (ru)
BR0007672B1 (ru)
BR0007487B1 (ru)
BR0007468B1 (ru)
BR0006866B1 (ru)
BR0006854B1 (ru)
BR0006634B1 (ru)
CN303074447S (ru)
BR0005041B1 (ru)
BR0004687B1 (ru)
BR0003928B1 (ru)
BR0003751B1 (ru)
BR0003746B1 (ru)
BR0003686B1 (ru)